Sjogren's Syndrome - Treatment Options, Symptoms, Causes & Diagnosis from MedifocusHealth

Sjogren's Syndrome > What Your Doctor is Reading About Sjogren's Syndrome > Clinical Trials

Clinical Trials

1. Improvement of Sjogren's syndrome after two infusions of rituximab (anti-CD20).

Author: Devauchelle-Pensec V; Pennec Y; Morvan J; Pers JO; Daridon C; Jousse-Joulin S; Roudaut A; Jamin C; Renaudineau Y; Roue IQ; Cochener B; Youinou P; Saraux A;
Institution: Hopital de la Cavale Blanche, CHU Brest, France.
Journal: Arthritis Rheum. 2007 Mar 15;57(2):310-7.
Abstract URL: Click here to view abstract

2. Efficacy prediction of cevimeline in patients with Sjogren's syndrome.

Author: Yamada H; Nakagawa Y; Wakamatsu E; Sumida T; Yamachika S; Nomura Y; Mishima K; Saito I; Yamada H; Nakagawa Y; Wakamatsu E; Sumida T; Yamachika S; Nomura Y; Mishima K; Saito I; Yamada H; Nakagawa Y; Wakamatsu E; Sumida T; Yamachika S; Nomura Y; Mishima K; Saito I;
Institution: Department of Pathology, Tsurumi University School of Dental Medicine, 2-1-3 Tsurumi, Tsurumi-ku, Yokohama, 230-8501, Japan.
Journal: Clin Rheumatol. 2007 Aug;26(8):1320-7. Epub 2007 Jan 13.
Abstract URL: Click here to view abstract

3. Safety and efficacy of leflunomide in primary Sjogren's syndrome: a phase II pilot study.

Author: van Woerkom JM; Kruize AA; Geenen R; van Roon EN; Goldschmeding R; Verstappen SM; van Roon JA; Bijlsma JW; van Woerkom JM; Kruize AA; Geenen R; van Roon EN; Goldschmeding R; Verstappen SM; van Roon JA; Bijlsma JW; van Woerkom JM; Kruize AA; Geenen R; van Roon EN; Goldschmeding R; Verstappen SM; van Roon JA; Bijlsma JW;
Institution: Department of Rheumatology & Clinical Immunology, F 02.127, University Medical Center, PO Box 85500, 3508 GA Utrecht, The Netherlands.
Journal: Ann Rheum Dis. 2007 Aug;66(8):1026-32. Epub 2007 Jan 12.
Abstract URL: Click here to view abstract

4. Lacrimal punctum occlusion in the treatment of severe keratoconjunctivitis Sicca caused by Sjogren syndrome: a uniocular evaluation.

Author: Mansour K; Leonhardt CJ; Kalk WW; Bootsma H; Bruin KJ; Blanksma LJ;
Institution: Department of Ophthalmology, Academic Hospital, University of Groningen, Groningen, The Netherlands. k.mansour@ohk.umcg.nl
Journal: Cornea. 2007 Feb;26(2):147-50.
Abstract URL: Click here to view abstract

5. Effect of dehydroepiandrosterone administration on fatigue, well-being, and functioning in women with primary Sjogren syndrome: a randomised controlled trial.

Author: Hartkamp A; Geenen R; Godaert GL; Bootsma H; Kruize AA; Bijlsma JW; Derksen RH;
Institution: Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands.
Journal: Ann Rheum Dis. 2008 Jan;67(1):91-7. Epub 2007 Jun 1.
Abstract URL: Click here to view abstract

6. Efficacy and safety of mizoribine for the treatment of Sjogren's syndrome: a multicenter open-label clinical trial.

Author: Nakayamada S; Saito K; Umehara H; Ogawa N; Sumida T; Ito S; Minota S; Nara H; Kondo H; Okada J; Mimori T; Yoshifuji H; Sano H; Hashimoto N; Sugai S; Tanaka Y;
Institution: First Department of Internal Medicine, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu, 807-8555, Japan.
Journal: Mod Rheumatol. 2007;17(6):464-9. Epub 2007 Dec 20.
Abstract URL: Click here to view abstract

7. Sjogren's Syndrome Disease Damage Index and disease activity index: scoring systems for the assessment of disease damage and disease activity in Sjogren's syndrome, derived from an analysis of a cohort of Italian patients.

Author: Vitali C; Palombi G; Baldini C; Benucci M; Bombardieri S; Covelli M; Del Papa N; De Vita S; Epis O; Franceschini F; Gerli R; Govoni M; Bongi SM; Maglione W; Migliaresi S; Montecucco C; Orefice M; Priori R; Tavoni A; Valesini G; Vitali C; Palombi G; Baldini C; Benucci M; Bombardieri S; Covelli M; Del Papa N; De Vita S; Epis O; Franceschini F; Gerli R; Govoni M; Bongi SM; Maglione W; Migliaresi S; Montecucco C; Orefice M; Priori R; Tavoni A; Valesini G; Vitali C; Palombi G; Baldini C; Benucci M; Bombardieri S; Covelli M; Del Papa N; De Vita S; Epis O; Franceschini F; Gerli R; Govoni M; Bongi SM; Maglione W; Migliaresi S; Montecucco C; Orefice M; Priori R; Tavoni A; Valesini G; Vitali C; Palombi G; Baldini C; Benucci M; Bombardieri S; Covelli M; Del Papa N; De Vita S; Epis O; Franceschini F; Gerli R; Govoni M; Bongi SM; Maglione W; Migliaresi S; Montecucco C; Orefice M; Priori R; Tavoni A; Valesini G; Vitali C; Palombi G; Baldini C; Benucci M; Bombardieri S; Covelli M; Del Papa N; De Vita S; Epis O; Franceschini F; Gerli R; Govoni M; Bongi SM; Maglione W; Migliaresi S; Montecucco C; Orefice M; Priori R; Tavoni A; Valesini G;
Institution: Villamarina Hospital, Piombino, Italy. c.vitali@yahoo.it
Journal: Arthritis Rheum. 2007 Jul;56(7):2223-31.
Abstract URL: Click here to view abstract

8. The efficacy of cevimeline hydrochloride in the treatment of xerostomia in Sjogren's syndrome in southern Chinese patients: a randomised double-blind, placebo-controlled crossover study.

Author: Leung KC; McMillan AS; Wong MC; Leung WK; Mok MY; Lau CS;
Institution: Oral Rehabilitation, Faculty of Dentistry, The University of Hong Kong, Hong Kong, China.
Journal: Clin Rheumatol. 2008 Apr;27(4):429-36. Epub 2007 Sep 26.
Abstract URL: Click here to view abstract

9. Augmented interferon-alpha pathway activation in patients with Sjogren's syndrome treated with etanercept.

Author: Mavragani CP; Niewold TB; Moutsopoulos NM; Pillemer SR; Wahl SM; Crow MK;
Institution: Mary Kirkland Center for Lupus Research, Hospital for Special Surgery, 535 East 70th Street, New York, NY 10021, USA.
Journal: Arthritis Rheum. 2007 Dec;56(12):3995-4004.
Abstract URL: Click here to view abstract

10. An evaluation of the efficacy of a cyclosporine-based dry eye therapy when used with marketed artificial tears as supportive therapy in dry eye.

Author: Sall KN; Cohen SM; Christensen MT; Stein JM; Sall KN; Cohen SM; Christensen MT; Stein JM;
Institution: Sall Eye Care, Bellflower, CA, USA.
Journal: Eye Contact Lens. 2006 Jan;32(1):21-6.
Abstract URL: Click here to view abstract

11. Lamivudine is not effective in primary Sjogren's syndrome.

Author: Gescuk B; Wu AJ; Whitcher JP; Daniels TE; Lund S; Fye K; Davis JC Jr;
Institution: Clinical Trials Center, Division of Rheumatology, University of California, San Francisco, 533 Parnassus Avenue Box 0633 Room U383, San Francisco, CA 94143-0633, USA.
Journal: Ann Rheum Dis. 2005 Sep;64(9):1326-30. Epub 2005 Feb 11.
Abstract URL: Click here to view abstract

12. The impact of topical cyclosporine A emulsion 0.05% on the outcomes of patients with keratoconjunctivitis sicca.

Author: Stonecipher K; Perry HD; Gross RH; Kerney DL;
Institution: Southeastern Laser and Refractive Center, Greensboro, NC, USA.
Journal: Curr Med Res Opin. 2005 Jul;21(7):1057-63.
Abstract URL: Click here to view abstract

13. Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years.

Author: Barber LD; Pflugfelder SC; Tauber J; Foulks GN;
Institution: Department of Ophthalmology, University of Arkansas, Little Rock, Arkansas 72205, USA.
Journal: Ophthalmology. 2005 Oct;112(10):1790-4.
Abstract URL: Click here to view abstract

14. Rituximab treatment in patients with primary Sjogren's syndrome: an open-label phase II study.

Author: Pijpe J; van Imhoff GW; Spijkervet FK; Roodenburg JL; Wolbink GJ; Mansour K; Vissink A; Kallenberg CG; Bootsma H;
Institution: Department of Oral and Maxillofacial Surgery, University Medical Center Groningen, Groningen, The Netherlands. j.pijpe@kchir.umcg.nl
Journal: Arthritis Rheum. 2005 Sep;52(9):2740-50.
Abstract URL: Click here to view abstract

15. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjogren's syndrome.

Author: Seror R; Sordet C; Guillevin L; Hachulla E; Masson C; Ittah M; Candon S; Le Guern V; Aouba A; Sibilia J; Gottenberg JE; Mariette X;
Institution: Department of Rheumatology, Hopital Bicetre, Assistance Publique-Hopitaux de Paris, Universite paris-Sud 11, INSERM U802, Le Kremlin Bicetre, France.
Journal: Ann Rheum Dis. 2007 Mar;66(3):351-7. Epub 2006 Sep 1.
Abstract URL: Click here to view abstract

16. Systemic sclerosis-associated Sjogren's syndrome and relationship to the limited cutaneous subtype: results of a prospective study of sicca syndrome in 133 consecutive patients.

Author: Avouac J; Sordet C; Depinay C; Ardizonne M; Vacher-Lavenu MC; Sibilia J; Kahan A; Allanore Y; Avouac J; Sordet C; Depinay C; Ardizonne M; Vacher-Lavenu MC; Sibilia J; Kahan A; Allanore Y; Avouac J; Sordet C; Depinay C; Ardizonne M; Vacher-Lavenu MC; Sibilia J; Kahan A; Allanore Y; Avouac J; Sordet C; Depinay C; Ardizonne M; Vacher-Lavenu MC; Sibilia J; Kahan A; Allanore Y;
Institution: Rene Descartes University, Medical Faculty, Hopital Cochin, France.
Journal: Arthritis Rheum. 2006 Jul;54(7):2243-9.
Abstract URL: Click here to view abstract

17. Epratuzumab (humanised anti-CD22 antibody) in primary Sjogren's syndrome: an open-label phase I/II study.

Author: Steinfeld SD; Tant L; Burmester GR; Teoh NK; Wegener WA; Goldenberg DM; Pradier O;
Institution: Department of Rheumatology, Erasme University Hospital, 808 Route de Lennik, Brussels 1070, Belgium. ssteinfe@ulb.ac.be
Journal: Arthritis Res Ther. 2006;8(4):R129.
Abstract URL: Click here to view abstract

18. Sjogren's syndrome is associated with and not secondary to systemic sclerosis.

Author: Salliot C; Mouthon L; Ardizzone M; Sibilia J; Guillevin L; Gottenberg JE; Mariette X;
Institution: Rheumatology Department, Paris-Sud 11 University, INSERM U802, France.
Journal: Rheumatology (Oxford). 2007 Feb;46(2):321-6. Epub 2006 Jul 28.
Abstract URL: Click here to view abstract

19. Suspension made with amniotic membrane: clinical trial.

Author: Bonci, P; Bonci, P; Lia, A;
Institution: Department of Ophthalmology, Eye Bank, S. Maria della Scaletta Hospital, Imola (BO) - Italy.
Journal: Eur J Ophthalmol 2005 Jul-Aug;15(4):441-5.
Abstract URL: Click here to view abstract

20. Effect of cevimeline on salivary components in patients with Sjogren syndrome.

Author: Suzuki, Kimihiro; Matsumoto, Mitsuyo; Nakashima, Masahiro; Takada, Kunio; Nakanishi, Takashi; Okada, Makoto; Ohsuzu, Fumitaka;
Institution: Internal Medicine I, National Defense Medical College, Tokorozawa, Japan. kogen@me.ndmc.ac.jp
Journal: Pharmacology 2005 May;74(2):100-5. Epub 2005 Feb 18.
Abstract URL: Click here to view abstract

21. Effects of the topical treatment with NSAIDs on corneal sensitivity and ocular surface of Sjogren's syndrome patients.

Author: Aragona, P; Stilo, A; Ferreri, F; Mobrici, M;
Institution: Department of Surgical Science, Section of Ophthalmology, University of Messina, Messina, Italy. paragona@unime.it
Journal: Eye 2005 May;19(5):535-9.
Abstract URL: Click here to view abstract